ASCO® 2023 Insights: "INDIGO Trial on Vorasidenib vs. Placebo in Patients With Residual or Recurrent Grade 2 Glioma With an IDH1/2 Mutation"
By
Dana-Farber Cancer Institute
FEATURING
Patrick Wen
By
Dana-Farber Cancer Institute
FEATURING
Patrick Wen
Login to view comments.
Click here to Login